

P66 40774

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rakoczy, P.E. et al. : Art Unit:
 Serial No.: 09/065,082 : Examiner:
 Filed: April 23, 1998 :
 For: **HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND
 VEGF ANTISENSE DNA TO TREAT ABNORMAL RETINAL
 VASCULARIZATION**

LETTER

Assistant Commissioner for Patents
 Washington, DC 20231
 Box PCT

Sir/Madam:


Responsive to the Notification of Missing Requirements of July 22, 1998, applicants are enclosing copies of a Letter, Declaration by Inventors and Rule 32 Power of Attorney filed with the Patent Office on July 13, 1998. No surcharge is enclosed as the Declaration was provided within 20 or 30 months from the priority date.

The Assistant Commissioner for Patents is hereby authorized to charge to Deposit Account No. 16-2460 payment of all fees associated with this correspondence, including fees for extensions of time, which, if necessary, are hereby requested.

Respectfully submitted.
 PRETTY, SCHROEDER & POPLAWSKI


Date:

9/25/98


 Viviana Amzel, Ph.D.
 Reg. No. 30,930
 Attorney for Applicants

444 South Flower Street
 19th Floor
 Los Angeles, CA 90071
 (213) 622-7700 Ph.
 (213) 489-4210 Fax

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 Box PCT on 9/25/98 by Joanne H. Housen.



RECEIVED
 98 NOV -4, AM 8:26
 GROUP 180

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rakoczy, P.E. et al. : Art Unit:
Serial No.: 09/065,082 : Examiner:
Filed: April 23, 1998 :
For: **HYALURONIC ACID AS DNA CARRIER FOR GENE THERAPY AND
VEGF ANTISENSE DNA TO TREAT ABNORMAL RETINAL
VASCULARIZATION**

LETTER


Assistant Commissioner for Patents
Washington, DC 20231
Box PCT

Sir/Madam:

Enclosed for filing are a Declaration, and Rule 32 Power of Attorney for the above-identified case.

The Assistant Commissioner for Patents is hereby authorized to charge to Deposit Account No. 16-2460 payment of all fees associated with this correspondence, including fees for extensions of time, which, if necessary, are hereby requested.

Respectfully submitted.
PRETTY, SCHROEDER & POPLAWSKI




Date: July 13, 1998

Viviana Amzel, Ph.D.
Reg. No. 30,930
Attorney for Applicants

444 South Flower Street
19th Floor
Los Angeles, CA 90071
(213) 622-7700 Ph.
(213) 489-4210 Fax

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 Bpx PCT on July 13, 1998 by Joanne H. Housen



RECEIVED
98 NOV -4 AM 8:26
GROUP 180

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Rakoczy, P.E. et al.

Docket No.

P66 40774

Serial No.

09/065,082

Filing Date

April 23, 1998

Examiner

Group Art Unit

Invention: Hyaluronic Acid as DNA Carrier for Gene Therapy and VEGF Antisense DNA to Treat Abnormal Retinal Vascularization

I hereby certify that this Declaration and Rule 32 Power of Attorney

(Identify type of correspondence)


is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The

Assistant Commissioner for Patents, Washington, D.C. 20231 on

Box PCT.July 13, 1998
(Date)

Joanne H. Housen

(Typed or Printed Name of Person Mailing Correspondence)


(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.

✓ 09/065082



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: ASSISTANT COMMISSIONER FOR PATENTS
Box PCT
Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/065,082	RAKOCZY	P P6640774
INTERNATIONAL APPLICATION NO.		
PCT/AU96/00664		
I.A. FILING DATE	PRIORITY DATE	
10/22/96	10/22/96	
DATE MAILED: 07/22/98		

5621

VIVIANA AMZEL
PRETTY SCHROEDER & POPLAWSKI
444 SOUTH FLOWER ST
19TH FLOOR
LOS ANGELES CA 90071

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as
- ☐ a Designated Office (37 CFR 1.494),
 - ☒ an Elected Office (37 CFR 1.495):
 - ☒ U.S. Basic National Fee.
 - ☒ Copy of the international application in:
 - ☐ a non-English language.
 - ☒ English.
 - ☐ Translation of the international application into English.
 - ☐ Oath or Declaration of inventors(s) for DO/EO/US.
 - ☐ Copy of Article 19 amendments.
 - ☐ Translation of Article 19 amendments into English.
 - ☒ The International Preliminary Examination Report in English and its Annexes, if any.
 - ☐ Translation of Annexes to the International Preliminary Examination Report into English.
 - ☒ Preliminary amendment(s) filed Apr. 23, 1998 and _____
 - ☒ Information Disclosure Statement(s) filed Apr. 23, 1998 and _____
 - ☐ Assignment document.
 - ☐ Power of Attorney and/or Change of Address.
 - ☐ Substitute specification filed _____
 - ☐ Statement Claiming Small Entity Status.
 - ☒ Priority Document.
 - ☒ Copy of the International Search Report ☐ and copies of the references cited therein.
 - ☐ Other:
2. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- ☐ a. Translation of the application into English. Note a processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
 - ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
 - ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
 - ☒ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the international application number and international filing date.
 - ☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
 - ☒ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).
3. Additional claim fees of \$ _____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

ALL OF THE ITEMS SET FORTH IN 2(a)-2(d) AND 3 ABOVE MUST BE SUBMITTED WITHIN ONE MONTH FROM THE DATE OF THIS NOTICE OR BY ☐ 21 OR ☒ 31 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

4. Translation of the Annexes **MUST** be submitted no later than the time period set above or the annexes will be cancelled. Note processing fee will be required if submitted later than 30 months from the priority date.
5. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

Enclosed: ☐ PCT/DO/EO/917 ☐ Notice of Defective Translation
☐ PTO-875
FORM PCT/DO/EO/905 (December 1997)

John Anderson
Telephone: (703) 308-9116

Please acknowledge receipt of the accompanying:

- ☒ Letter
☒ Copy of Letter filed 7/13/98
☒ Copy of Declaration
☒ Copy of Notification

Applicant's Name: Rakoczy, E.P. et al.

Serial Number: 09/065,082

Examiner's Name:

Filing Date: April 23, 1998

Group Art Unit:

Title: Hyaluronic Acid as DNA Carrier for Gene Therapy and VEGF Antisense DNA to Treat
Abnormal Retinal Vascularization

☒ Fee ~~\$100.00~~ Enclosed

Check No.

Our Docket No.: P66 40774

Client: Griffith

Atty/Secy: VA/jhh

Date Mailed: September 25, 1998

Date Due: May 22, 1999

404 Rec'd PCT/PTO 28 SEP 1998

Place your receiving date stamp hereon and return this card.

T:\root\misc\postcard.wpd